CordenPharma Adds Manufacturing Line for Vet Drug Products
CordenPharma is investing €10 Million in a new line at its Plankstadt, Germany site.
CordenPharma, a contract development and manufacturing organization (CDMO) for APIs, drug products, and packaging, will invest €10 million (almost $12 million) in a new manufacturing line dedicated to producing veterinary drug products for 500-kg scale batch sizes. This new line is part of a production plant that is dedicated to veterinary drug products.
The expansion of the production capabilities at CordenPharma Plankstadt (Germany) is the result of a new, long-term custom manufacturing agreement for an animal health applications. Work began in the second quarter of 2017, with a targeted mechanical completion by the 2nd quarter of 2018 and commercial supply for the global launch campaign is expected to start in the second half of 2018.
The new production line will allow the fully contained handling of highly potent APIs in a dedicated facility for the manufacturing of veterinary drug products, said Frank Hähner, managing director of CordenPharma Plankstadt, in a press release.
This investment in CordenPharma Plankstadt is the latest of several expansions that the company has made in 2017, including other projects in Plankstadt, as well as new projects in Colorado.
Source: CordenPharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
